CGEN Quote, Financials, Valuation and Earnings

Kamada Ltd. has a net margin of -369.06% compared to Compugen Ltd.'s net margin of 11.27%. Compugen Ltd.'s return on equity of -51.8% beat Kamada Ltd.'s return on equity of 7.91%.

Compugen Ltd. has a consensus price target of $6.25, signalling upside risk potential of 311.18%. On the other hand Kamada Ltd. has an analysts' consensus of $13.00 which suggests that it could grow by 83.36%. Given that Compugen Ltd. has higher upside potential than Kamada Ltd., analysts believe Compugen Ltd. is more attractive than Kamada Ltd..

Compugen Ltd. has a beta of 2.818, which suggesting that the stock is 181.823% more volatile than S&P 500. In comparison Kamada Ltd. has a beta of 0.917, suggesting its less volatile than the S&P 500 by 8.347%.

Compugen Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kamada Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.20 per share. Compugen Ltd. pays -- of its earnings as a dividend. Kamada Ltd. pays out -- of its earnings as a dividend.

Compugen Ltd. quarterly revenues are $1.9M, which are smaller than Kamada Ltd. quarterly revenues of $47M. Compugen Ltd.'s net income of -$7M is lower than Kamada Ltd.'s net income of $5.3M. Notably, Compugen Ltd.'s price-to-earnings ratio is 55.83x while Kamada Ltd.'s PE ratio is 19.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compugen Ltd. is 20.51x versus 2.33x for Kamada Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Nasus Pharma has a net margin of -369.06% compared to Compugen Ltd.'s net margin of --. Compugen Ltd.'s return on equity of -51.8% beat Nasus Pharma's return on equity of --.

Compugen Ltd. has a consensus price target of $6.25, signalling upside risk potential of 311.18%. On the other hand Nasus Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Compugen Ltd. has higher upside potential than Nasus Pharma, analysts believe Compugen Ltd. is more attractive than Nasus Pharma.

Compugen Ltd. has a beta of 2.818, which suggesting that the stock is 181.823% more volatile than S&P 500. In comparison Nasus Pharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Compugen Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nasus Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Compugen Ltd. pays -- of its earnings as a dividend. Nasus Pharma pays out -- of its earnings as a dividend.

Compugen Ltd. quarterly revenues are $1.9M, which are larger than Nasus Pharma quarterly revenues of --. Compugen Ltd.'s net income of -$7M is higher than Nasus Pharma's net income of --. Notably, Compugen Ltd.'s price-to-earnings ratio is 55.83x while Nasus Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compugen Ltd. is 20.51x versus -- for Nasus Pharma. Usually stocks with elevated PS ratios are considered overvalued.

BiomX, Inc. has a net margin of -369.06% compared to Compugen Ltd.'s net margin of --. Compugen Ltd.'s return on equity of -51.8% beat BiomX, Inc.'s return on equity of -160.84%.

Compugen Ltd. has a consensus price target of $6.25, signalling upside risk potential of 311.18%. On the other hand BiomX, Inc. has an analysts' consensus of $399.00 which suggests that it could grow by 8150%. Given that BiomX, Inc. has higher upside potential than Compugen Ltd., analysts believe BiomX, Inc. is more attractive than Compugen Ltd..

Compugen Ltd. has a beta of 2.818, which suggesting that the stock is 181.823% more volatile than S&P 500. In comparison BiomX, Inc. has a beta of 1.558, suggesting its more volatile than the S&P 500 by 55.818%.

Compugen Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BiomX, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Compugen Ltd. pays -- of its earnings as a dividend. BiomX, Inc. pays out -- of its earnings as a dividend.

Compugen Ltd. quarterly revenues are $1.9M, which are larger than BiomX, Inc. quarterly revenues of --. Compugen Ltd.'s net income of -$7M is higher than BiomX, Inc.'s net income of -$9.2M. Notably, Compugen Ltd.'s price-to-earnings ratio is 55.83x while BiomX, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compugen Ltd. is 20.51x versus -- for BiomX, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Teva Pharmaceutical Industries Ltd. has a net margin of -369.06% compared to Compugen Ltd.'s net margin of 9.71%. Compugen Ltd.'s return on equity of -51.8% beat Teva Pharmaceutical Industries Ltd.'s return on equity of 10.27%.

Compugen Ltd. has a consensus price target of $6.25, signalling upside risk potential of 311.18%. On the other hand Teva Pharmaceutical Industries Ltd. has an analysts' consensus of $32.77 which suggests that it could grow by 3.25%. Given that Compugen Ltd. has higher upside potential than Teva Pharmaceutical Industries Ltd., analysts believe Compugen Ltd. is more attractive than Teva Pharmaceutical Industries Ltd..

Compugen Ltd. has a beta of 2.818, which suggesting that the stock is 181.823% more volatile than S&P 500. In comparison Teva Pharmaceutical Industries Ltd. has a beta of 0.668, suggesting its less volatile than the S&P 500 by 33.237%.

Compugen Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Teva Pharmaceutical Industries Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Compugen Ltd. pays -- of its earnings as a dividend. Teva Pharmaceutical Industries Ltd. pays out -- of its earnings as a dividend.

Compugen Ltd. quarterly revenues are $1.9M, which are smaller than Teva Pharmaceutical Industries Ltd. quarterly revenues of $4.5B. Compugen Ltd.'s net income of -$7M is lower than Teva Pharmaceutical Industries Ltd.'s net income of $436M. Notably, Compugen Ltd.'s price-to-earnings ratio is 55.83x while Teva Pharmaceutical Industries Ltd.'s PE ratio is 51.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compugen Ltd. is 20.51x versus 2.17x for Teva Pharmaceutical Industries Ltd.. Usually stocks with elevated PS ratios are considered overvalued.